Filing Details

Accession Number:
0000899243-20-006252
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-28 16:25:06
Reporting Period:
2020-02-26
Accepted Time:
2020-02-28 16:25:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1281933 K Douglas Bratton 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
1536054 Crestline Management, Lp 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
1626596 Crestline Investors, Inc. 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
1626597 Crestline Si (Gp), L.p. 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
1716958 Akdl, L.p. 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-02-26 3,894,764 $20.25 15,567,736 No 4 S Indirect By AKDL, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By AKDL, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 953,035 Indirect By Neuro Line Partners, L.P.
Footnotes
  1. These shares of common stock of Denali Therapeutics Inc. (the "Issuer") are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.
  2. (continued from footnote 1) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
  3. These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.
  4. (continued from footnote 3) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.